We are live on ! Find out more
P

Pfizer Portfolio holdings

AUM $170M
1-Year Est. Return 191.09%
This Fund
S&P 500
This Quarter Est. Return
+36.31%
1 Year Est. Return
+191.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$236M
AUM Growth
-$201M
Cap. Flow
-$225M
Cap. Flow %
-95.03%
Top 10 Hldgs %
95.36%
Holding
21
New
–
Increased
–
Reduced
–
Closed
3

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$164M
2
TRML
Tourmaline Bio
TRML
+$60.8M
3
EPIX
ESSA Pharma
EPIX
+$320K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
1
Oric Pharmaceuticals
ORIC
$1.41B
$44M 18.6%
5,376,344
– –
ARVN icon
2
Arvinas
ARVN
$575M
$41M 17.34%
3,457,815
– –
CELC icon
3
Celcuity
CELC
$4.46B
$34.8M 14.74%
349,406
– –
WVE icon
4
Wave Life Sciences
WVE
$1.05B
$31.9M 13.48%
1,875,000
– –
ALLO icon
5
Allogene Therapeutics
ALLO
$694M
$30.2M 12.76%
22,032,040
– –
ZURA icon
6
Zura Bio
ZURA
$532M
$15.6M 6.58%
2,970,022
– –
PYXS icon
7
Pyxis Oncology
PYXS
$194M
$8.09M 3.42%
7,032,770
– –
CRBU icon
8
Caribou Biosciences
CRBU
$157M
$7.46M 3.15%
4,690,431
– –
CRDF icon
9
Cardiff Oncology
CRDF
$76.7M
$6.78M 2.87%
2,411,575
– –
BHVN icon
10
Biohaven
BHVN
$2.21B
$5.71M 2.41%
505,645
– –
SPRO icon
11
Spero Therapeutics
SPRO
$70.1M
$5.5M 2.33%
2,362,348
– –
NXTC icon
12
NextCure
NXTC
$35M
$2.24M 0.95%
157,646
– –
ZNTL icon
13
Zentalis Pharmaceuticals
ZNTL
$258M
$1.29M 0.54%
953,834
– –
QTTB icon
14
Q32 Bio
QTTB
$450M
$922K 0.39%
277,777
– –
ANTX icon
15
AN2 Therapeutics
ANTX
$225M
$815K 0.34%
715,295
– –
BOLT icon
16
Bolt Biotherapeutics
BOLT
$6.32M
$171K 0.07%
31,305
– –
DNA icon
17
Ginkgo Bioworks
DNA
$468M
$24.3K 0.01%
2,928
– –
SENS icon
18
Senseonics Holdings Inc
SENS
$413M
$12K 0.01%
2,171
– –
BNTX icon
19
BioNTech
BNTX
$23B
– –
-1,658,361
Closed -$164M
EPIX
20
DELISTED
ESSA Pharma
EPIX
– –
-1,675,000
Closed -$320K
TRML
21
DELISTED
Tourmaline Bio
TRML
– –
-1,272,214
Closed -$60.8M

Similar funds

DWM
Daner Wealth Management Alpharetta, Georgia $170M AUM 15.3% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
MACM
MAC Alpha Capital Management Tampa, Florida $171M AUM
SNBOSCI
Security National Bank of Sioux City Iowa Sioux City, Iowa $169M AUM 18.07% 1-Year Est. Return
FVM
Forerunner Ventures Management San Francisco, California $169M AUM
AIM
Atlantic Investment Management New York $172M AUM 39.5% 1-Year Est. Return
PP
Pingora Partners Wilson, Wyoming $169M AUM 56.08% 1-Year Est. Return
TA
Tiptree Advisors New York $172M AUM 86.65% 1-Year Est. Return

Pfizer's Q4 2025 Portfolio in Review

As of Q4 2025, Pfizer held 21 positions worth $236M, down 46% from $437M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Pfizer withdrew a net $225M in Q4 2025, closing 3 positions. Its most notable exit was BioNTech, an estimated $164M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Pfizer fully exited BioNTech in Q4 2025, selling an estimated $164M.
  • Pfizer's ten largest holdings make up 95% of its $236M portfolio in Q4 2025.
  • Pfizer opened 0 new positions and closed 3 in Q4 2025.
  • Pfizer's portfolio value fell 46% quarter-over-quarter to $236M.

Based on Pfizer's 13F filing for Q4 2025, filed 12 Feb 2026.